JP7420827B2 - 抗il-36r抗体製剤 - Google Patents

抗il-36r抗体製剤 Download PDF

Info

Publication number
JP7420827B2
JP7420827B2 JP2021552832A JP2021552832A JP7420827B2 JP 7420827 B2 JP7420827 B2 JP 7420827B2 JP 2021552832 A JP2021552832 A JP 2021552832A JP 2021552832 A JP2021552832 A JP 2021552832A JP 7420827 B2 JP7420827 B2 JP 7420827B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524502A (ja
Inventor
デンキンガー,サンドラ・ニコル
シュタイナー,アンナ・マリア
カタヤマ,デリック・スペンサー
メーラ,ラジニ・プラサード
プレッサー,インゴ・ミヒャエル
シン,ラヴィジャ
ライト,サラ・ケイ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2022524502A publication Critical patent/JP2022524502A/ja
Priority to JP2023193220A priority Critical patent/JP2024020372A/ja
Application granted granted Critical
Publication of JP7420827B2 publication Critical patent/JP7420827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021552832A 2019-03-08 2020-03-05 抗il-36r抗体製剤 Active JP7420827B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023193220A JP2024020372A (ja) 2019-03-08 2023-11-13 抗il-36r抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815405P 2019-03-08 2019-03-08
US62/815,405 2019-03-08
PCT/US2020/021059 WO2020185479A1 (en) 2019-03-08 2020-03-05 Anti-il-36r antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023193220A Division JP2024020372A (ja) 2019-03-08 2023-11-13 抗il-36r抗体製剤

Publications (2)

Publication Number Publication Date
JP2022524502A JP2022524502A (ja) 2022-05-06
JP7420827B2 true JP7420827B2 (ja) 2024-01-23

Family

ID=70009446

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552832A Active JP7420827B2 (ja) 2019-03-08 2020-03-05 抗il-36r抗体製剤
JP2023193220A Pending JP2024020372A (ja) 2019-03-08 2023-11-13 抗il-36r抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023193220A Pending JP2024020372A (ja) 2019-03-08 2023-11-13 抗il-36r抗体製剤

Country Status (14)

Country Link
US (2) US11730812B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934617A1 (cg-RX-API-DMAC7.html)
JP (2) JP7420827B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210137520A (cg-RX-API-DMAC7.html)
CN (1) CN113543772A (cg-RX-API-DMAC7.html)
AU (1) AU2020238676B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016198A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132917A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002331A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192405A1 (cg-RX-API-DMAC7.html)
IL (1) IL286100B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021010783A (cg-RX-API-DMAC7.html)
PH (1) PH12021552150A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020185479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
WO2019177883A2 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
MX2023000763A (es) 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
CN114907477A (zh) * 2021-02-08 2022-08-16 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
BR112023014103A2 (pt) 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
WO2026041035A1 (zh) * 2024-08-20 2026-02-26 江苏恒瑞医药股份有限公司 一种包含il-36r/il-23结合蛋白的药物组合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504907A (ja) 1997-06-13 2002-02-12 ジェネンテク,インコーポレイテッド 抗体製剤
JP2007524602A (ja) 2003-04-04 2007-08-30 ジェネンテック・インコーポレーテッド 高濃度抗体及びタンパク質製剤
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
JP2015500633A (ja) 2011-11-16 2015-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗il−36r抗体
JP2018512157A (ja) 2015-04-15 2018-05-17 アナプティスバイオ インコーポレイティッド インターロイキン36受容体(il−36r)に対する抗体

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP1798286B1 (en) 1997-08-01 2011-09-07 Schering Corporation Mammalian cell membrane proteins and related reagents
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
CA2499891A1 (en) 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8034771B2 (en) 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
JP2010526066A (ja) 2007-04-23 2010-07-29 シェーリング コーポレイション 抗mdl−1抗体
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 il-22, il-17 및 il-1 패밀리 시토킨의 용도
EP2473528B1 (en) * 2009-09-03 2014-12-03 Ablynx N.V. Stable formulations of polypeptides and uses thereof
SG184355A1 (en) 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
KR102063028B1 (ko) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ang2 항체를 함유하는 안정화된 제형
RU2667643C2 (ru) 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
US20180008707A1 (en) 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
US10166993B2 (en) 2015-08-05 2019-01-01 Ford Global Technologies, Llc Customer driving mode for vehicles
EP3601350A1 (en) 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Anti il-36r antibodies combination therapy
WO2019177883A2 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
AU2019236105B2 (en) * 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
KR20210119407A (ko) 2018-12-27 2021-10-05 베링거 인겔하임 인터내셔날 게엠베하 수장 족저 농포증 치료용 항-il-36r 항체
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504907A (ja) 1997-06-13 2002-02-12 ジェネンテク,インコーポレイテッド 抗体製剤
JP2007524602A (ja) 2003-04-04 2007-08-30 ジェネンテック・インコーポレーテッド 高濃度抗体及びタンパク質製剤
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
JP2015500633A (ja) 2011-11-16 2015-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗il−36r抗体
JP2018512157A (ja) 2015-04-15 2018-05-17 アナプティスバイオ インコーポレイティッド インターロイキン36受容体(il−36r)に対する抗体

Also Published As

Publication number Publication date
IL286100B2 (en) 2024-12-01
TW202100141A (zh) 2021-01-01
AU2020238676A1 (en) 2021-09-16
JP2022524502A (ja) 2022-05-06
CN113543772A (zh) 2021-10-22
BR112021016198A2 (pt) 2021-11-03
US11730812B2 (en) 2023-08-22
US20200282053A1 (en) 2020-09-10
EP3934617A1 (en) 2022-01-12
WO2020185479A1 (en) 2020-09-17
CL2021002331A1 (es) 2022-06-17
IL286100A (en) 2021-10-31
US20230372480A1 (en) 2023-11-23
CA3132917A1 (en) 2020-09-17
PH12021552150A1 (en) 2022-08-15
IL286100B1 (en) 2024-08-01
MX2021010783A (es) 2021-09-30
KR20210137520A (ko) 2021-11-17
EA202192405A1 (ru) 2022-01-13
AU2020238676B2 (en) 2025-04-17
JP2024020372A (ja) 2024-02-14

Similar Documents

Publication Publication Date Title
US20230372480A1 (en) Anti-il-36r antibody formulations
US12559551B2 (en) Stabilized formulations containing anti-ANGPTL3 antibodies
CN109078182B (zh) 抗体制剂
KR101593285B1 (ko) 단일 도메인 항원 결합 분자의 제형
AU2020203306C1 (en) Stable anti-ifnar1 formulation
JP6769879B2 (ja) Gm−csf中和化合物を含む液体製剤
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
EA047696B1 (ru) Составы антител против il-36r
CN115812080A (zh) 含有抗ctla-4抗体的稳定调配物
HK40000750A (en) Antibody formulations
HK40000750B (en) Antibody formulations
HK1261758A1 (en) Antibody formulations
HK1210431B (en) Formulations of single domain antigen binding molecules
HK1160376B (en) Formulations of single domain antigen binding molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240111

R150 Certificate of patent or registration of utility model

Ref document number: 7420827

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150